1/6/22

Silicon Ranch Raises $775 Million in Equity Funding Led by Manulife Investment Management

10/25/21

Bausch + Lomb and Clearside Biomedical Announce FDA Approval of XIPERE™ (triamcinolone acetonide injectable suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis

10/19/21

Castle Biosciences to Acquire Cernostics

6/15/21

Clearside Biomedical Announces Positive Safety Results from Cohort 1 of OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD

4/27/21

Castle Biosciences Signs Definitive Agreement to Acquire Myriad myPath® Laboratory

3/2/21

G1 Therapeutics and Boehringer Ingelheim Announce Commercial Availability of COSELA™ (trilaciclib), the Only FDA-Approved Multilineage Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression

2/12/21

FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression

12/22/20

The 21 Best Stocks to Buy for 2021

12/18/20

Castle Biosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

12/9/20

G1 Therapeutics Presents Final Phase 2 Clinical Data on Trilaciclib in Combination with Chemotherapy in Metastatic Triple-Negative Breast Cancer Demonstrating Significant Improvement in Overall Survival at 2020 San Antonio Breast Cancer Symposium

11/2/20

Castle Biosciences Announces Commercial Launch of DecisionDx DiffDx-Melanoma

10/8/20

Castle Biosciences Announces Expanded Medicare Coverage for DecisionDx-Melanoma in Cutaneous Melanoma

9/2/20

Castle Biosciences Announces Commercial Launch of DecisionDx-SCC

6/24/20

Castle Biosciences Announces Pricing of $74.0 Million Public Offering of Common Stock

10/29/19

Castle Biosciences Presents Clinical Validation Study for its Cutaneous Squamous Cell Carcinoma Prognostic Test at the American Society for Dermatologic Surgery (ASDS) 2019 Annual Meeting

10/7/19

Newly Published Systematic Review Confirms Strength of Evidence and Outlines Appropriate Use Criteria for Integration of DecisionDx-Melanoma in Management of Patients with Cutaneous Melanoma

7/29/19

Castle Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

6/18/19

G1 THERAPEUTICS ANNOUNCES UPDATED RESULTS FROM PHASE 2 TRIAL OF TRILACICLIB IN COMBINATION WITH CHEMOTHERAPY SHOWED STATISTICALLY SIGNIFICANT IMPROVEMENT IN OVERALL SURVIVAL IN WOMEN WITH METASTATIC TRIPLE-NEGATIVE BREAST CANCER

3/6/19

Publication of Independent Prospective, Multicenter Study Reinforces Accuracy of DecisionDx-Melanoma Test Recurrence Risk Prediction

2/20/19

Clearside Receives Notification of FDA Acceptance of NDA Filing for XIPERE

2/7/19

Newly Published Study Shows DecisionDx-Melanoma Prognostic Test Accurately Identified Risk for Patients with Melanoma of the Head and Neck

1/30/19

Castle Biosciences Announces Publication of Prospective Multicenter Study Demonstrating that its DecisionDx-Melanoma Test can Inform Sentinel Lymph Node Biopsy Decisions

1/7/19

Castle Biosciences’ DecisionDx-Melanoma Test Identifies High-Risk Melanoma Patients Among Those Traditionally Staged as Low Risk in Newly Published Study

12/6/18

Castle Biosciences Announces the Appointment of Genomic Health CFO G. Bradley Cole to its Board of Directors

10/18/18

Castle Biosciences Announces Medicare Coverage for the DecisionDx-Melanoma Test in Cutaneous Melanoma

7/30/18

Castle Biosciences Presents Data Demonstrating the DecisionDx-Melanoma Test Improved AJCC-Based Risk Prediction for Melanoma Recurrence and Metastasis

5/31/18

Clearside Biomedical Announces Positive Topline Results from Phase 2 Clinical Trial of CLS-TA Used with Eylea in Patients with Diabetic Macular Edema

4/16/18

G1 Therapeutics Announces Initiation of Phase 1b/2 Clinical Trial of G1T38 in Combination with Tagrisso for EGFR-Mutant Non-Small Cell Lung Cancer

3/28/18

Castle Biosciences Announces Inclusion of DecisionDx-UM Prognostic Test in New NCCN Guidelines for Uveal Melanoma

3/15/18

G1 Therapeutics Announces Positive Trilaciclib Phase 2a Topline Data Showing Robust Myelopreservation Bene ts in Patients with Small Cell Lung Cancer

3/5/18

Clearside Biomedical Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial of CLS-TA in Macular Edema Associated with Non-Infectious Uveitis

12/18/17

G1 Therapeutics Added to Nasdaq Biotechnology Index

9/18/17

G1 Therapeutics Added to Russell 2000®, 3000® and Microcap® Indexes

7/13/17

G1 Therapeutics Appoints Sir Andrew Witty to Board of Directors

6/9/17

Myomo, Inc. Completes Historic Initial Public Offering

5/30/17

G1 Therapeutics to Present Clinical Data on CDK4/6 Inhibitor Trilaciclib at the 2017 American Society of Clinical Oncology Annual Meeting

3/29/17

G1 Therapeutics Announces Presentations at the 2017 American Association for Cancer Research Annual Meeting

1/10/17

G1 Therapeutics Initiates Three Drug Development Programs in Breast Cancer

9/21/16

NuSirt Biopharma and OWL Metabolomics Partner to Advance Treatment of NASH / Non-alcoholic Steatohepatitis

6/1/16

Clearside Biomedical, Inc. Announces Pricing of Initial Public Offering

5/11/16

G1 Therapeutics Secures $47 Million Series C Financing